Johnson & Johnson’s Janssen Pharmaceuticals division is providing refunds to 340B covered entities for overcharges on 14 NDCs during Q1 2020.
The U.S. Health Resources and Services Administration (HRSA) posted J&J’s refund notice yesterday. The company said the 340B price revisions “were due to standard restatements of Medicaid pricing data made to” the Centers for Medicare & Medicaid Services.
Johnson & Johnson’s Janssen Pharmaceuticals division is providing refunds to 340B covered entities for overcharges on 14 NDCs during Q1 2020.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
